EPS Miss Report | 2026-04-23 | Quality Score: 94/100
Users can access market analysis covering earnings reports, institutional flows, and stock price movements.
This analysis evaluates Amgen Inc. (NASDAQ: AMGN) following recent analyst adjustments, positive clinical trial results, and its inclusion on Insider Monkey’s 10 Most Undervalued Dow Stocks list. With first-quarter 2026 earnings scheduled for post-market release on April 30, Guggenheim has revised i
Live News
As of April 23, 2026, two key near-term catalysts have shifted investor sentiment for Amgen ahead of its upcoming quarterly earnings print. On April 6, the company announced statistically significant positive topline results from a Phase 3 trial evaluating a subcutaneous on-body injector formulation of TEPEZZA, its blockbuster treatment for moderate-to-severe active thyroid eye disease (TED). The trial met its primary endpoint of proptosis (eye bulge) response at 24 weeks, alongside all key seco
Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataCross-asset analysis helps identify hidden opportunities. Traders can capitalize on relationships between commodities, equities, and currencies.Some investors prioritize simplicity in their tools, focusing only on key indicators. Others prefer detailed metrics to gain a deeper understanding of market dynamics.Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataSome investors prioritize simplicity in their tools, focusing only on key indicators. Others prefer detailed metrics to gain a deeper understanding of market dynamics.
Key Highlights
Three core takeaways stand out for current and prospective AMGN investors. First, the subcutaneous TEPEZZA Phase 3 trial delivered robust, clinically meaningful efficacy: the 77% proptosis response rate for the subQ formulation was more than 3.9 times the 19.6% rate recorded for the placebo arm, with a mean 3.17mm reduction in eye bulge versus 0.80mm for placebo. The subQ delivery method, which matches the efficacy of the existing IV formulation, will expand access to TED patients by eliminating
Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataInvestors often monitor sector rotations to inform allocation decisions. Understanding which sectors are gaining or losing momentum helps optimize portfolios.Scenario planning based on historical trends helps investors anticipate potential outcomes. They can prepare contingency plans for varying market conditions.Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataCross-market analysis can reveal opportunities that might otherwise be overlooked. Observing relationships between assets can provide valuable signals.
Expert Insights
From a fundamental analysis perspective, Amgen’s near-term risk-reward profile is balanced, supporting Guggenheim’s Neutral rating even as the stock screens as undervalued relative to historical and peer benchmarks. The bull case for AMGN is anchored in the upcoming TEPEZZA subQ launch, which is expected to add $400 to $600 million in annual incremental revenue by 2028, according to consensus sell-side estimates, as it captures 30% of new TED patient starts within 18 months of expected FDA approval in late 2026. Additionally, Amgen’s diversified pipeline of 19 late-stage assets across oncology, cardiovascular, and rare disease indications reduces single-asset risk, while its $18 billion share repurchase program authorized in 2025 provides ongoing support for share prices. That said, material downside risks limit upside in the near term: upcoming patent expiries for key drugs including Prolia and Xgeva in 2027 are expected to erase roughly $1.8 billion in annual revenue by 2029, absent offsetting pipeline wins, while competitive pressure from new GLP-1 cardiovascular therapies could weigh on sales of Amgen’s Repatha franchise. Guggenheim’s $351 price target implies a 4.8% upside from AMGN’s April 23 closing price of $334.92, a relatively modest total return compared to higher-growth segments of the market. As noted in Insider Monkey’s market coverage, select undervalued AI equities offer significantly higher upside potential in the current market cycle, with lower downside risk tied to onshoring trends and Trump-era tariff policies that support domestic AI hardware and software manufacturing. For investors with a moderate risk tolerance and focus on defensive, income-generating equities, AMGN remains a compelling hold at current levels, with the upcoming Q1 earnings release offering a catalyst for upward re-rating if the company delivers on consensus revenue estimates of $7.2 billion and adjusted EPS of $4.52. For growth-oriented investors, however, allocations to niche AI equities may generate superior risk-adjusted returns over the 12-month investment horizon. Investors should monitor Amgen’s Q1 earnings call for management guidance on the TEPEZZA subQ launch timeline, as well as updates on pipeline progress for its lead KRAS inhibitor sotorasib, which is being evaluated in expanded first-line lung cancer indications. Disclosure: No positions held in AMGN or related derivatives at the time of publication. (Word count: 1172)
Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataAnalytical platforms increasingly offer customization options. Investors can filter data, set alerts, and create dashboards that align with their strategy and risk appetite.Predictive analytics are increasingly part of traders’ toolkits. By forecasting potential movements, investors can plan entry and exit strategies more systematically.Amgen Inc. (AMGN) - Guggenheim Raises Price Target Ahead of Q1 Earnings, Supported by Positive TEPEZZA Phase 3 DataWhile data access has improved, interpretation remains crucial. Traders may observe similar metrics but draw different conclusions depending on their strategy, risk tolerance, and market experience. Developing analytical skills is as important as having access to data.